Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 183

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Treatment Patterns and Attitudes Among US-Based Physicians in Using BTK Inhibitors to Treat Relapsed/Refractory CLL and MCL

Ryan P. Topping, Timothy A. Quill, Farrukh T. Awan, Jonathon B. Cohen

Blood (2024) 144 (Supplement 1): 7601.

https://doi.org/10.1182/blood-2024-208406

Published: 2024

Journal Articles

Differential Antiviral IgG Titer Decay Rates after Frontline Chemoimmunotherapy in Patients with Aggressive B Cell Lymphoma

Andres Chang, Alyssa Leal, Michael Churnetski, Lilin Lai, Susanne Linderman, Hasan Ahmed, Colin B O'Leary, Rustom Antia, Madhav V. Dhodapkar, Mehul Suthar, Jean L. Koff, Jonathon B Cohen, Rafi Ahmed

Blood (2024) 144 (Supplement 1): 6242.

https://doi.org/10.1182/blood-2024-200324

Published: 2024

Journal Articles

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Anne W Beaven, Susan M. Geyer, Jonathon B. Cohen, Tycel Phillips, Travis Dockter, Priyanka A. Pophali, Gita Thanarajasingam, Gina L. Mazza, Alvaro J Alencar, Shira N. Dinner, Eric D. Hsi, Meng Welliver, Daniel Nikcevich, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 1661.3.

https://doi.org/10.1182/blood-2024-207372

Published: 2024

Journal Articles

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Blood (2024) 144 (Supplement 1): 6199.

https://doi.org/10.1182/blood-2024-204481

Published: 2024

Journal Articles

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Mazie Tsang, Urshila Durani, Jonathan R Day, Melissa C. Larson, Matthew Holets, Kathleen J Yost, Jonathon B. Cohen, Jonathan W. Friedberg, Izidore S. Lossos, Peter Martin, Brad S. Kahl, Thomas M. Habermann, Loretta Nastoupil, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Carla Casulo, Matthew J. Maurer

Blood (2024) 144 (Supplement 1): 7598.

https://doi.org/10.1182/blood-2024-210968

Published: 2024

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Jason T Romancik, Katelin Baird, Angelo Thomas Marra, Amelia Langston, Pamela B. Allen, Jonathon B. Cohen, Jean L. Koff, Mary Jo Lechowicz, Jeffrey M. Switchenko, Kristie A. Blum

Blood (2024) 144 (Supplement 1): 1717.

https://doi.org/10.1182/blood-2024-211784

Published: 2024

Journal Articles

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Pranav Santapuram, Jason T Romancik, Jonathon B Cohen, Melissa Kives, Manali Rupji, Javier Pinilla-Ibarz, Kami J. Maddocks, Craig A. Portell, Joanna M. Rhodes, Brian K. Link

Blood (2024) 144 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2024-204002

Published: 2024

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Blood (2024) 144 (Supplement 1): 3736.

https://doi.org/10.1182/blood-2024-211091

Published: 2024

Journal Articles

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 473.

https://doi.org/10.1182/blood-2024-201626

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2024) 144 (Supplement 1): 2345.

https://doi.org/10.1182/blood-2024-210594

Published: 2024

Journal Articles

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Blood (2024) 144 (Supplement 1): 3754.

https://doi.org/10.1182/blood-2024-201896

Published: 2024

Journal Articles

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 3093.

https://doi.org/10.1182/blood-2024-208111

Published: 2024

Journal Articles

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Andres Chang, Adam Pelletier, Donald J McGuire, Maria Tsagiopoulou, Maria Karipidou, Amy Ayers, Alyssa Leal, Michael Churnetski, Colin B O'Leary, Jeffrey M. Switchenko, Carl Davis, David A. Frank, Jean L. Koff, Jonathon B Cohen, Rafick-Pierre Sekaly, Kostas Stamatopoulos, Christopher R. Flowers, Rafi Ahmed

Blood (2024) 144 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2024-200302

Published: 2024

Journal Articles

Is rituximab retro in mantle cell lymphoma?

Christine E. Ryan, Jonathon B. Cohen

Blood (2024) 144 (3): 241–243.

https://doi.org/10.1182/blood.2024024711

Published: 2024

Journal Articles

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Blood (2023) 142 (Supplement 1): 67.

https://doi.org/10.1182/blood-2023-190316

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Treatment Patterns and Attitudes Among US-Based Physicians in Using BTK Inhibitors to Treat Relapsed/Refractory CLL and MCL

Differential Antiviral IgG Titer Decay Rates after Frontline Chemoimmunotherapy in Patients with Aggressive B Cell Lymphoma

Trial in Progress - Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma

Molecular Subtyping of DLBCL Patients from the Oncology Research Information Exchange Network

Understanding the Patient Perspective on Treatment Preferences for Follicular Lymphoma

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Clinical Features and Outcomes of Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Single-Center Analysis

Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study

Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

PD-1 Expression Identifies Proliferating Chronic Lymphocytic Leukemia Cells and Informs Response and Resistance to BTK Inhibitor Therapy

Is rituximab retro in mantle cell lymphoma?

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only